Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer

被引：2
|
作者：
Zou, Tao [1 ,2 ]
Meyerson, Matthew [1 ,2 ,3 ,4 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Broad Inst Harvard & MIT, Cambridge, MA USA
[3] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA
[4] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 06期
关键词：
D O I：
10.1158/0008-5472.CAN-19-0231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Circulating tumor DNA (ctDNA) holds great promise as a noninvasive diagnostic tool to guide treatment for patients with lung cancer. Two studies by Phallen and colleagues and Anagnostou and colleagues correlated sensitive measures of ctDNA with clinical responses to tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors, respectively, in patients with non-small cell lung cancer (NSCLC). Together, these studies further highlight the potential clinical utility of serial ctDNA monitoring in patients with NSCLC undergoing treatment with both targeted therapies and immunotherapies.
引用
收藏
页码：1038 / 1040
页数：3
相关论文
共 50 条
  • [41] Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer
    Paci, Massimiliano
    Maramotti, Sally
    Bellesia, Enrica
    Formisano, Debora
    Albertazzi, Laura
    Ricchetti, Tommaso
    Ferrari, Guglielmo
    Annessi, Valerio
    Lasagni, Daniela
    Carbonelli, Cristiano
    De Franco, Salvatore
    Brini, Maria
    Sgarbi, Giorgio
    Lodi, Renzo
    LUNG CANCER, 2009, 64 (01) : 92 - 97
  • [42] The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment
    Sueoka-Aragane, Naoko
    Nakashima, Chiho
    Yoshida, Hironori
    Matsumoto, Naohisa
    Iwanaga, Kentaro
    Ebi, Noriyuki
    Nishiyama, Akihiro
    Yatera, Kazuhiro
    Kuyama, Shoichi
    Fukuda, Minoru
    Ushijima, Sunao
    Umeguchi, Hitomi
    Harada, Daijiro
    Kashiwabara, Kosuke
    Suetsugu, Takayuki
    Fujimoto, Nobukazu
    Tanaka, Fumihiro
    Uramoto, Hidetaka
    Yoshii, Chiharu
    Nakatomi, Katsumi
    Koh, Genju
    Seki, Nobuhiko
    Aoe, Keisuke
    Nosaki, Kaname
    Inoue, Koji
    Takamori, Ayako
    Kawaguchi, Atsushi
    CANCER MEDICINE, 2021, 10 (12): : 3873 - 3885
  • [43] Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer
    Chae, Young Kwang
    Davis, Andrew A.
    Agte, Sarita
    Pan, Alan
    Simon, Nicholas I.
    Iams, Wade T.
    Cruz, Marcelo R.
    Tamragouri, Keerthi
    Rhee, Kyunghoon
    Mohindra, Nisha
    Villaflor, Victoria
    Park, Wungki
    Lopes, Gilberto
    Giles, Francis J.
    ONCOLOGIST, 2019, 24 (06): : 820 - 828
  • [44] A Comparative Analysis of Genomic Alterations by Tumor Tissue and Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer
    Woo, G.
    Kim, S. H.
    Suh, K. J.
    Kim, Y. J.
    Chung, J.
    Lee, B.
    Kwon, N.
    Seo, J.
    Lee, J. S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S706 - S706
  • [45] Prognostic Role of Circulating Tumor DNA (ctDNA) and Immune Cell Biomarkers in Non-Small Cell Lung Cancer (NSCLC)
    Chae, Y. K.
    Agte, S.
    Davis, A.
    Pan, A.
    Simon, N.
    Mohindra, N.
    Villaflor, V.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2242 - S2242
  • [46] The heterogeneity of circulating lung tumor cells from non-small cell lung cancer patients
    Kong, S. L.
    Tan, S. J.
    Lim, T. K. H.
    Poh, H. M.
    Yeo, T. Z. X.
    Liu, X.
    Chua, Y. W.
    Bhagat, A. A.
    Lim, W. T.
    Hillmer, A. M.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S80 - S80
  • [47] Early Response of Circulating Tumor DNA Predict the Efficacy of Nivolumab in Patients with Non-small Cell Lung Cancer
    Iijima, Yuki
    Hirotsu, Yosuke
    Amemiya, Kenji
    Mochizuki, Hitoshi
    Oyama, Toshio
    Nakagomi, Takahiro
    Uchida, Yoshinori
    Kobayashi, Yoichi
    Tsutsui, Toshiharu
    Kakizaki, Yumiko
    Goto, Taichiro
    Miyashita, Yoshihiro
    Omata, Masao
    CANCER SCIENCE, 2018, 109 : 920 - 920
  • [48] Commentary: Circulating tumor DNA in resectable non-small cell lung cancer: Emerging canary in the coal mine
    Sachdeva, Uma M.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 168 (05):
  • [49] Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor
    Ku, Bo Mi
    Kim, Yeon Jeong
    Park, Donghyun
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    Sun, Jong-Mu
    ONCOLOGY, 2022, 100 (04) : 228 - 237
  • [50] Cerebrospinal fluid circulating tumor DNA for the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer
    Miao, Qian
    Zheng, Xinlong
    Zheng, Xiaobin
    Jiang, Kan
    Lin, Gen
    Zhang, Longfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345